Science Moderna and Merck’s Personalized mRNA Melanoma Vaccine Meets Primary Endpoints in Landmark Phase 3 Trial August 20, 2026 Moderna and Merck announced on August 19 that a phase 3 trial of their experimental personalized mRNA cancer therapy, intismeran, in combination with Keytruda (pembrolizumab), met two key endpoints in…